Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis

Archives of Neurology

Volumn 66, Issue 10, 2009, Pages 1216-1223

  Cepok, Sabine ^a   Schreiber, Herbert ^b   Hoffmann, Steve ^c   Zhou, Dun ^d   Neuhaus, Oliver ^d   Von Geldern, Gloria ^d   Hochgesand, Sonja ^d   Nessler, Stefan ^a   Rothhammer, Veith ^a   Lang, Michael ^b   Hartung, Hans Peter ^d   Hemmer, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MS Practice Study Group   (Germany)

^c Interdisciplinary Center for Bioinformatics   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CCL1 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NEUTRALIZING ANTIBODY; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT INTERFERON; RNA;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GERMANY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; RECEPTOR UPREGULATION; TREATMENT RESPONSE; BIOSYNTHESIS; BLOOD; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; OUTPATIENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS; UPREGULATION; VALIDATION STUDY;

ADULT; AUTOANTIBODIES; CHEMOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; OUTPATIENTS; RECEPTORS, CCR1; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STATISTICS, NONPARAMETRIC; UP-REGULATION; YOUNG ADULT;

EID: 70350450975     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.138     Document Type: Article

References (50)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
2. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996;85(3):299-302. (Pubitemid 26160700)
3. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 1996;6(3):243-257.
4. Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3(7):569-581. (Pubitemid 37328676)
5. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol. 2001;2(2):95-101.
6. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity. 2001;14(4):377-386. (Pubitemid 32441590)
7. Ransohoff RM. The chemokine system in neuroinflammation: an update. J Infect Dis. 2002;186(suppl 2):S152-S156.
8. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610-621.
9. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol. 1998;84(2):238-249. (Pubitemid 28248412)
10. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of the interferon-γ-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2000;26(2):133-142. (Pubitemid 30251386)
11. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol. 1998;86(1):20-29. (Pubitemid 28293946)
12. Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103(6):807-815. (Pubitemid 29152626)
13. + T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A. 1999;96(12):6873-6878.
14. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129(pt 1):200-211. (Pubitemid 43063771)
15. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2004;101(30):11064-11069. (Pubitemid 38989584)
16. Sørensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol. 2001;8(6):665-672. (Pubitemid 35015232)
17. Moreira MA, Tilbery CP, Monteiro LP, Teixeira MM, Teixeira AL. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand. 2006;114(2):109-113. (Pubitemid 44034258)
18. Scarpini E, Galimberti D, Baron P, et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci. 2002;195(1):41-46. (Pubitemid 34175097)
19. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol. 2001;115(1-2):192-198. (Pubitemid 32245668)
20. Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72(4):498-502. (Pubitemid 34289567)
21. Mahad DJ, Lawry J, Howell SJL, Woodroofe MN. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult Scler. 2003;9(2):189-198. (Pubitemid 36426993)
22. Muller DM, Pender MP, Greer JM. Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. Curr Drug Targets Inflamm Allergy. 2004;3(3):279-290. (Pubitemid 39206656)
23. Zipp F, Hartung HP, Hillert J, et al; CCR1 Antagonist Study Group. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology. 2006;67(10):1880-1883.
24. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-β antibodies in MS patients. Neurology. 2003;61(10):1444-1446.
25. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis [published correction appears in Am J Hum Genet. 2008;83(4):541]. Am J Hum Genet. 2008;83(2):219-227.
26. Vartanian T, Sölberg Sørensen P, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol. 2004;251(suppl 2):II25-II30.
27. Hartung H-P, Polman C, Bertolotto A, et al. Neutralising antibodies to interferon β in multiple sclerosis: expert panel report. J Neurol. 2007;254(7):827-837. (Pubitemid 47222316)
28. Jacobs LD, Cookfair DL, Rudick RA, et al; Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294.
29. Kieseier BC, Hartung H-P. Current disease-modifying therapies in multiple sclerosis. Semin Neurol. 2003;23(2):133-146.
30. Zang YCQ, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-β. J Neuroimmunol. 2001;112(1-2):174-180.
31. Sørensen TL, Sellebjerg F. Selective suppression of chemokine receptor CXCR3 expression by interferon-β1a in multiple sclerosis. Mult Scler. 2002;8(2):104-107. (Pubitemid 34256745)
32. Teleshova N, Pashenkov M, Huang Y-M, et al. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol. 2002;249(6):723-729. (Pubitemid 34651755)
33. Buttmann M, Merzyn C, Rieckmann P. Interferon-β induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol. 2004;156(1-2):195-203. (Pubitemid 39304200)
34. Krakauer M, Sorensen PS, Khademi M, Olsson T, Sellebjerg F. DynamicT-lymphocyte chemokine receptor expression induced by interferon-β therapy in multiple sclerosis. Scand J Immunol. 2006;64(2):155-163. (Pubitemid 44034320)
35. Szczuciński A, Losy J. Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis. Folia Neuropathol. 2004;42(1):15-18. (Pubitemid 38515269)
36. Satoh J, Nanri Y, Tabunoki H, Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis. BMC Neurol. May 19, 2006;6:18. doi:10.1186/1471-2377-6-18.
37. Lund BT, Ashikian N, Ta HQ, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol. 2004;155(1-2):161-171. (Pubitemid 39165789)
38. Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM. Novel interferon-β-induced gene expression in peripheral blood cells. J Leukoc Biol. 2007;82(5):1353-1360. (Pubitemid 350133533)
39. Kivisäkk P, Cotleur AC, Lee JC, Rudick RA, Ransohoff RM. Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells. J Neuroimmunol. 2003;141(1-2):150-154. (Pubitemid 37289008)
40. Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol. 2001;50(3):349-357. (Pubitemid 32848737)
41. Vallittu AM, Saraste M, Airas L. CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol Res. 2007;29(8):763-766. (Pubitemid 350255147)
42. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
43. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491-1497.
44. Proudfoot AEI, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A. 2003;100(4):1885-1890. (Pubitemid 36254543)
45. Paoletti S, Petkovic V, Sebastiani S, Danelon MG, Uguccioni M, Gerber BO. A rich chemokine environment strongly enhances leukocyte migration and activities. Blood. 2005;105(9):3405-3412. (Pubitemid 40628179)
46. + regulatory T cells. J Exp Med. 2001;194(6):847-853.
47. + regulatory and Th2 effector lymphocytes. J Immunol. 2006;177(10):6940-6951.
48. Ferguson SSG. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev. 2001;53(1):1-24.
49. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell α chemoattractant (CXCL11). J Immunol. 2001;167(12):7084-7093. (Pubitemid 33144205)
50. Dagan-Berger M, Feniger-Barish R, Avniel S, et al. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion, and internalization in response to CXCL11. Blood. 2006;107(10):3821-3831. (Pubitemid 43726782)